A previous study published in the BMJ showing no reduction in MI risk with angiotensin receptor antagonists was "incomplete, inaccurate and misleading"

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1490, 2005-01, pp. : 21-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk-benefit assessment of angiotensin II receptor antagonists

By Shusterman Neil  

Expert Opinion on Drug Safety, Vol. 1, Iss. 2, 2002-07 ,pp. : 137-152

Informa Healthcare

Access to resources Recommend Favorite

Angiotensin II receptor antagonists -

By Burnier M.   Brunner H.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 5, 1997-05 ,pp. : 489-500

Informa Healthcare

Access to resources Recommend Favorite

Angiotensin receptor antagonists lower cancer risk?

By  

Reactions Weekly, Vol. 1, Iss. 1345, 2011-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Can Angiotensin Receptor Antagonists Be Used Safely in Patients with Previous ACE Inhibitor-Induced Angioedema?

By Howes L.G.  

Drug Safety, Vol. 25, Iss. 2, 2002-01 ,pp. : 73-76

Adis International

Access to resources Recommend Favorite

Economic Benefits of Treating High-Risk Hypertension with Angiotensin II Receptor Antagonists (Blockers)

By Coca Antonio  

Clinical Drug Investigation, Vol. 28, Iss. 4, 2008-01 ,pp. : 211-220

Adis International

Access to resources Recommend Favorite